Nexium I.V. (Esomeprazole)

Esomeprazole belongs to the proton pump inhibitor class. It binds irreversibly to the H+/K+ ATPase enzyme on gastric parietal cells, blocking the final step of acid secretion. This results in a sustained decrease in gastric acidity, allowing damaged tissue to heal and reducing reflux‑related irritation.

The specific dose and infusion rate of Nexium I.V. are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to each individual case, following local prescribing guidelines.

Safety data for esomeprazole in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians must evaluate each case and discuss possible risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nexium I.V. provides rapid, controlled acid suppression via intravenous delivery, which can be advantageous in patients unable to take oral medications. Compared with oral PPIs, it offers faster onset and reliable plasma concentrations, making it suitable for acute care settings.

Nexium I.V. should be stored at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and avoid freezing. Follow any additional handling instructions provided by the manufacturer.

Nexium I.V. is given as an intravenous infusion by a qualified healthcare professional. The solution is diluted in an appropriate compatible IV fluid and administered over a prescribed period, typically ranging from a few minutes to an hour, depending on the clinical protocol.

Serious adverse events, though rare, can include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhea, Stevens‑Johnson syndrome, and significant liver enzyme elevations. Patients should be monitored for any signs of these conditions during treatment.

Patients with known hypersensitivity to esomeprazole, other proton pump inhibitors, or any component of the formulation should avoid Nexium I.V. Additionally, caution is advised for individuals with severe hepatic impairment or those taking medications that have major interactions with PPIs.